嘉事堂(002462) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥12,561,786,991.15, representing a 29.35% increase compared to ¥9,711,728,693.95 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥175,169,586.50, up 29.12% from ¥135,661,448.28 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥170,034,213.83, reflecting a 30.00% increase from ¥130,794,996.51 in the same period last year[20]. - The basic earnings per share increased by 27.66% to ¥0.60 from ¥0.47 in the previous year[20]. - The company achieved a revenue of 12.562 billion yuan in the first half of 2021, representing a year-on-year growth of 29.35%[29]. - The net profit attributable to the listed company was 175 million yuan, an increase of 29.12% compared to the previous year[29]. - The total profit for the first half of 2021 was CNY 430,764,218.24, compared to CNY 314,449,772.89 in the same period last year, marking a rise of 37.0%[120]. - The company's operating profit reached CNY 435,333,242.72, an increase of 39.5% from CNY 312,082,838.90 in the previous year[120]. - The total comprehensive income for the first half of 2021 was CNY 311,244,856.45, compared to CNY 235,278,418.18 in the same period of 2020, reflecting a growth of 32.3%[120]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 71.15% to ¥79,692,687.05 from ¥276,189,753.86 in the same period last year[20]. - The net cash flow from investing activities worsened by 61.60% to -¥8,058,483.83, due to new business expansion and fixed asset investments[37]. - The net cash flow from financing activities increased by 109.40% to -¥597,580,668.91, resulting from reduced bank borrowings and increased dividends from subsidiaries[37]. - The net increase in cash and cash equivalents was -¥525,946,465.69, a significant decline of 3,615.70% compared to -¥14,154,860.74 in the previous year, mainly due to reduced bank borrowings[37]. - Cash and cash equivalents decreased to CNY 1,503,120,716.78 from CNY 2,018,504,935.00 at the end of 2020, representing a decline of approximately 25.4%[109]. - The ending balance of cash and cash equivalents was ¥1,352,822,100.11, a decrease from ¥1,417,209,067.94 at the end of the previous year[128]. Assets and Liabilities - Total assets at the end of the reporting period were ¥14,146,071,146.95, a slight increase of 0.09% from ¥14,133,717,238.25 at the end of the previous year[20]. - The total liabilities of the company were not explicitly stated but can be inferred from the balance sheet data provided[110]. - The company's total equity increased to ¥5,371,576,609.41 from ¥5,324,031,026.96, indicating a positive trend in shareholder value[112]. - The company's total assets at the end of the reporting period were approximately 3,034.86 million yuan, indicating growth in asset value[144]. Operational Strategies - The company focused on enhancing its drug sales in key hospitals, resulting in a significant increase in collaboration with upstream and downstream clients[28]. - The high-value consumables sales business continued to grow steadily, supported by the company's brand advantages and professional resources[28]. - The company optimized logistics resources and strengthened cooperation with well-known foreign pharmaceutical companies, improving service efficiency[28]. - The company actively implemented a merger and acquisition strategy to capitalize on industry consolidation opportunities, enhancing its national business layout[31]. - The company emphasized risk management and internal control systems to ensure the safety of state-owned assets and improve operational efficiency[32]. - The company is committed to exploring new business models, including medical device supply chain services and in-hospital information services, to create new profit growth points[33]. Shareholder Information - The company reported a total of 291,707,100 shares outstanding, with 85.60% being unrestricted shares[93]. - The largest shareholder, China Everbright Medical Health Industry Co., Ltd., holds 14.36% of the shares, totaling 41,876,431 shares[95]. - The company did not distribute cash dividends or issue new shares from capital reserves during the reporting period[61]. Research and Development - The company reported a significant increase in research and development expenses, although specific figures are not provided, indicating a commitment to innovation[117]. - The company plans to continue its focus on research and development for new products and technologies to enhance market competitiveness[141]. Financial Reporting and Compliance - The half-year financial report has not been audited, indicating a need for further financial scrutiny[71]. - The financial statements are prepared based on the "Enterprise Accounting Standards" and reflect the company's financial position as of June 30, 2021, and its operating results for the first half of 2021[154]. - The company follows a calendar year for its accounting period, from January 1 to December 31[155].